Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report

A 53-year-old man was affected by a sporadic metastatic medullary thyroid cancer (MTC), widespread to cervical and mediastinal lymph nodes, lungs, liver, and cerebellum. Over the 10 years from the initial diagnosis, the patient was treated with two tyrosine kinase inhibitors (TKIs) (i.e. vandetanib and lenvatinib off-label). After 1 year from surgery (total thyroidectomy with lymph node dissection of central and left latero-cervical...